Law360, New York (January 19, 2011, 3:36 PM EST) -- A federal judge Wednesday found the patent for Novo Nordisk A/S diabetes drug Prandin invalid because of obviousness and unenforceable due to inequitable conduct, paving the way for Caraco Pharmaceutical Laboratories Ltd. to market a generic version.
The decision by Judge Avern Cohn of the U.S. District Court for the Eastern District of Michigan comes after a six-year legal battle over whether the patent could be sustained.
The judge ruled that the idea covered by the patent to combine repaglinide with metformin as a combination therapy...
Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.